Yahoo Finance Live’s Brad Smith breaks down how stocks are moving in early trading.
(Bloomberg) -- The UK has granted the world’s first approval for a Covid-19 vaccine targeting a variant in a bid to sharpen its response to an evolving coronavirus. The country’s Medicines and Healthcare products Regulatory Agency cleared Moderna Inc.’s bivalent mRNA booster vaccine for adults, according to a statement Monday, in a move paving the way for it to potentially form part of Britain’s autumn booster campaign.Moderna’s bivalent shot targets two strains - half of the dose works against
Currently, Novavax (NVAX) has only one marketed product in its portfolio, its protein-based COVID-19 vaccine. However, it is lagging in competition behind mRNA-based vaccines.